Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function
- 1 January 1990
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 34 (1) , 17-20
- https://doi.org/10.1128/aac.34.1.17
Abstract
Lomefloxacin pharmacokinetics were investigated in 6 normal subjects and 24 uremic patients after a single oral dose of 400 mg. In subjects with normal renal function, the peak level in plasma averaged 3.5 +/- 0.9 micrograms/ml (mean +/- standard deviation) and was obtained at 1.3 +/- 0.9 h. The absorption rate constant was 3.8 +/- 1.6 h-1. The terminal half-life was 7.77 +/- 0.95 h. The apparent volume of distribution was 2.54 +/- 0.66 liters/kg. Total body and renal clearances were 259 +/- 83 and 200 +/- 55 ml/min per 1.73 m2, respectively. The percentage of the dose recovered unchanged in 48-h urine was 80.6 +/- 2.8. In uremic patients, the terminal half-life increased in relation to the degree of renal failure: from 8 h in normal subjects to 38 h in severely uremic patients (glomerular filtration rate, less than 10 ml/min). Renal insufficiency did not significantly modify the peak level in plasma, the time to peak, the apparent volume of distribution, or the nonrenal clearance of lomefloxacin. The dialysis clearance of lomefloxacin was 54 +/- 13 ml/min. Linear relationships were found between lomefloxacin pharmacokinetic parameters and glomerular filtration rate data. Dosage adjustments are necessary in uremic patients.This publication has 8 references indexed in Scilit:
- Pharmacokinetics and tissue penetration of orally administered lomefloxacinAntimicrobial Agents and Chemotherapy, 1988
- Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral dosesAntimicrobial Agents and Chemotherapy, 1988
- In vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agentsAntimicrobial Agents and Chemotherapy, 1988
- Clinical Pharmacokinetics of the Newer Antibacterial 4-QuinolonesClinical Pharmacokinetics, 1988
- In vitro and in vivo activity of NY-198, a new difluorinated quinoloneAntimicrobial Agents and Chemotherapy, 1987
- Ofloxacin pharmacokinetics in renal failureAntimicrobial Agents and Chemotherapy, 1987
- Clinical PharmacokineticsNew England Journal of Medicine, 1975
- Statistical estimations in pharmacokineticsJournal of Pharmacokinetics and Biopharmaceutics, 1974